Andy is an entrepreneur and investor with an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. He is currently Chairman of Arecor, Congenica, Abcodia, and Babraham Bioscience Technologies Ltd (BBT) at the Babraham Research Campus and is a Director of Ieso Digital Health, Silence Therapeutics plc, Cancer Research Technology (commercial arm of CR-UK), and Sensiia. He is an advisor to several investment funds including Cambridge Innovation Capital and the UCL Technology Fund and was, until recently, a director of Cambridge University Hospitals NHS Foundation Trust.
Andy is a Cambridge Graduate with a PhD in Chemistry and an early career spanning positions with ICI (now AstraZeneca) and PA Technology. He was a founder and executive director of Chiroscience plc until its merger with Celltech in 1999 and since that time he has founded, invested in and helped to scale more than 25 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels. He received a CBE for services to life-science investment in 2015.
David has over 30 years' experience of business leadership, and in particular leading significant business transformation, gained while working for organisations such as British Gas, QinetiQ and the UK Research Councils. His extensive experience is also diverse, ranging from procuring jet fighters to leading major IT and operational transformation projects. David has been instrumental in many programmes leading to step change for the organisations he has worked with, including an innovative £5.6Bn contract for a previous employer. David also has a history of unlocking difficult business situations, bringing parties together and enabling progress. He has a passion for encouraging and helping people to have ambitions, and then to achieve these ambitions.
Although still active in his Executive role as Executive Director, Finance & Campus Operations with BBSRC, David’s Non-Executive Director experience spans fifteen years across a diverse portfolio of organisations.
David is a Fellow of: The Chartered Institute of Management Accountants, The Royal Society of Biology and The Institute of Directors.
Clive Page is a Professor of Pharmacology, King’s College London and Director of the Sackler Institute of Pulmonary Pharmacology, King’s College London. Clive’s main research interests are in the pharmacology of inflammation and respiratory disease and he has published over 250 scientific papers.
Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, an AIM listed Company developing new drugs for the treatment of Respiratory Diseases. He is a Non Executive Director of Babraham Bioscience Technologies Ltd, as well as being a Trustee of the Babraham Institute in Cambridge and a Non Executive Director of the Board of Peptinnovate Ltd, PreP Biopharma and EpiEndo. Clive started his early career in the Pharmaceutical Industry at Sandoz Ltd, Basel, Switzerland and regularly consults to both the Pharmaceutical and Biotech Industry.
Clive is a recent former Chairman of the Animal Science Group of the Society of Biology and has contributed widely to the public debate about the use of animals in Research.
He was awarded the Society of Biology President’s Medal in 2012 for an outstanding contribution to the life sciences over the previous year. He is a fellow of the Royal Society of Biology and the British Pharmacological Society.
In 2017, Clive was awarded an OBE for Services to Pharmacology.
Jo is an experienced and successful investment professional with more than 10 years in the private equity industry. A qualified accountant, ACA, by training, she has worked in the corporate finance departments of FTSE 100 and FTSE 250 companies.
She is a Non Executive Director on Octopus AIM VCT plc and Babraham Bioscience Technologies Ltd (BBT), at the Babraham Research Campus. She is also a mentor on the Accelerate Program at the Judge Business School, Cambridge.
Jo has had significant board exposure, having held a number of non-executive posts. Having been a member of the Investment Committee of a leading private equity house, Jo is experienced in investment appraisal. Skilled in the evaluation of businesses, her strengths include identifying value creation opportunities at both a revenue and profit level. She has supported businesses in growth through investment and cost management, with a wealth of experience of developing business plans and working with businesses to secure appropriate financing.
Passionate about growing businesses, Jo has worked closely with entrepreneurs/management teams. She has a wealth of experience of arranging, working with and managing complicated shareholder structures, including a broad range of stakeholder groups. She has a proven track record of working with businesses to drive strategic initiatives and deliver outstanding financial results.
Previous non executive roles include Classic Hospitals Ltd, a group of ten private acute hospitals, IDH, the largest provider of NHS dentistry in the UK, and Verna Care, a manufacturer of infection control products.
She has a chemistry degree from Oxford University.
Jane Osbourn is VP Research and Development for MedImmune in Cambridge. MedImmune was formerly Cambridge Antibody Technology (CAT) and is now the global biologics research and development arm of AstraZeneca. An expert in antibody engineering, she has authored many key publications and patents, and made a significant contribution to the discovery and development of marketed drugs (Humira and Benlysta) and more than 40 clinical candidates. She has worked across many therapy areas, heading CAT’s oncology portfolio before becoming VP of Research for CAT and VP R&D for MedImmune Cambridge in 2008. She also leads a global team, based in Gaithersburg US, focused on the development of biosuperior antibody therapies.
Jane is passionate about the development of the UK biotechnology sector and was elected Chair of the Board of Directors of the BioIndustry Association (the UK biotechnology trade association) in 2015. To help support development of biotech in the Cambridge cluster she is also a Director of Babraham Bioscience Technologies Ltd (BBT) and a Director of Cambridge Enterprise. In addition, she has presented at a number of parliamentary Select Committees and has previously served as a Member of the UK Medical Research Council Industry Grant Award Assessment Panel. In 2016 she was recognised in the PharmaVoice 100, and also in Fierce Pharma’s “Fierce Women in Biopharma” – one of 15 women in the global industry noteworthy for their leadership, providing mentorship and helping increase opportunities for women in science.
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557